You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Silicon Valley Startup Jungla has a 10-year vision of its founders to improve large-scale correlation of mutations and disease.
After raising $320M in venture capital, Tempus hopes to sequence 100,000 samples in 2019 as it expands its precision medicine program into depression and diabetes.
The investigators showed that template-free Cas9 editing is capable of repair to a predicted genotype, allowing for correction of disease-associated mutations.
Scripps Research Translational Institute has teamed with Nvidia to create a center of excellence for AI in genomics and wearable sensors.
At AMP, the companies announced a partnership to add Paragon Genomics' NGS target enrichment technologies to the flagship Sophia AI platform worldwide.
The company aims to commercialize ProstaGene's PCaTest, which uses a 16-gene panel to determine the overall outcome of a patient's prostate cancer.
The company has not released data on its method, but describes a circulating tumor DNA approach that has similarities to what other firms are pursuing.
Some partners are implementing their solutions on the Azure cloud while others will accept output from Microsoft's genomics pipeline as input into their solutions.
With an SBIR Phase II grant in hand, Michigan startup Parabricks is adding both speed and AI to variant calling as it eyes a Series A round next year.
The chatbot developed with Clear Genetics follows up with patients after genetic testing and educates family members at risk for inheriting the same mutations.
The Wall Street Journal reports that Russia's announcement of a coronavirus vaccine approval was met with concern as safety testing has not yet been completed.
New Scientist writes there aren't much data available on the accuracy of the two rapid COVID-19 tests the UK plans to roll out.
In PNAS this week: downstream effect of oncoprotein fusion, epigenetic changes influence tRNAs in colon cancer, and more.
Nature News reports that recent proposed changes to the US National Science Foundation have raised concerns about a shift away from the agency's focus on basic research.